DeLiver Pharma ApS: Financial statements 2023
CVR: 39432714
Source: annual report 2023, Danish Business Authority
01/01/2023 – 31/12/2023
DeLiver Pharma ApS (CVR 39432714) has filed annual accounts for 2023. In 2023, the company reported a gross profit of DKK 118,663 and a net result of DKK 107,283 compared with DKK -29,331 the year before. Equity in the 2023 report amounted to DKK 216,770. The solvency ratio was 79.9%.
- Gross Profit
- DKK 118,663
- Profit/Loss
- DKK 107,283
- Equity
- DKK 216,770
- Total Assets
- DKK 271,360
- Employees
- 0
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2023 | - | 119K | 107K | 217K | 0 |
| 2022 | - | -18K | -29K | 109K | - |
| 2021 | - | -22K | -147K | 139K | - |
| 2020 | - | -20K | -114K | 246K | - |
| 2019 | 79K | 51K | -12K | 220K | - |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record, straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
DeLiver Pharma ApS has published its annual report for 2022. Gross profit came to DKK -17,951, and the net result was DKK -29,331.
About DeLiver Pharma ApS
DeLiver Pharma ApS is a Danish company of the type Anpartsselskab based in Faaborg, founded in 2018. The company is registered under the industry Fremstilling af farmaceutiske præparater. The management consists of Niels Jonas Heilskov Graversen. The board consists of Jens Kristian Damsgaard (chair), Holger Jon Møller, Niels Jonas Heilskov Graversen and Søren Kragh Moestrup. The company's owners include MOESTRUP HOLDING 2007 ApS, MØLLER HOLDING 2007 ApS and PHIDEAS ApS. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of DKK -20,487 and a net result of DKK -31,867 compared with DKK -21,682 the year before. Equity in the 2025 report amounted to DKK 163,221.